Publisher: Bentham Science Publishers
E-ISSN: 1873-4286|18|12|1663-1676
ISSN: 1381-6128
Source: Current Pharmaceutical Design, Vol.18, Iss.12, 2012-04, pp. : 1663-1676
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Triterpenes have been reported to induce cell death. One relevant group of this family of compounds is cucurbitacins, which have been studied as inducers of apoptosis in various cancer cell lines. The most significant mechanisms with regard to the apoptotic effects of cucurbitacins are their ability to modify transcriptional activities via nuclear factors or genes and their capability to activate or inhibit pro- or anti-apoptotic proteins. Still, while the majority of studies on these compounds have dealt with their apoptotic effects on cancer cell lines, several research groups have also explored their anti-inflammatory activities. In general, cucurbitacins are considered to be selective inhibitors of the JAK/STAT pathways; however, other mechanisms may be implicated in their apoptotic effects, including the MAPK pathway (known to be important for cancer cell proliferation and survival), PARP cleavage, expression of active caspase-3, decreased pSTAT3 and JAK3 levels, as well as decreases in various downstream STAT3 targets such as Mcl-1, Bcl-2, Bcl-xL, and cyclin D3, all of which are implicated in apoptosis and the cell cycle. Taking all these effects into account, cucurbitacins may prove useful in the treatment of different kinds of cancers, especially when used with other cytostatic agents.
Related content
Current Medicinal Chemistry, Vol. 13, Iss. 22, 2006-09 ,pp. :
Liverworts-Potential Source of Medicinal Compounds
Current Pharmaceutical Design, Vol. 14, Iss. 29, 2008-10 ,pp. :
Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry, Vol. 24, Iss. 40, 2018-01 ,pp. :